An Evaluation of Pentoxifylline in HIV-Positive Persons With Symptomatic HIV Infection and a Karnofsky Score > 40 Percent and < 100 Percent

Launched by COMMUNITY RESEARCH INITIATIVE OF NEW ENGLAND · Aug 30, 2001

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• Concurrent Medication:
• Allowed:
• • Stable antiretroviral therapy.
• • Maintenance medication for opportunistic infection.
• Patients must have:
• • HIV positivity.
• NOTE:
• • Patients on an antiretroviral must have received it for at least 2 months and have no currently perceived need to change or add to the regimen for the next 3 months.
• Prior Medication:
• Allowed:
• • Antiviral therapy (provided patient has been on such therapy for at least 2 months at study entry and dose is stable).
• • Exclusion Criteria
• Co-existing Condition:
• Patients with the following symptoms and conditions are excluded:
• • Evidence of active opportunistic infection or malignancy requiring high-dose systemic chemotherapy (only patients who are 30 days from a diagnosis of an opportunistic infection and on appropriate maintenance medication are allowed).
• • Known significant intolerance or hypersensitivity to theophylline, theobromine (chocolate), or caffeine, for reasons other than dyspepsia.
• • Inability to swallow tablets (gastric feeding tubes are allowed).
• • Active bleeding disorder or major bleeding source, including peptic ulcer or gastritis.
• • Any symptoms suggestive of concurrent illness that are not attributable to overall impairment by HIV or are not diagnosable based on the available evidence.
• • Not willing to comply with visit schedule and study procedures.
• Concurrent Medication:
• Excluded:
• • Concurrent use of the anticoagulant warfarin (Coumadin) and heparin.
• Prior Medication:
• Excluded:
• • Treatment with biologic response modifiers (e.g., interferon, interleukin) within 14 days prior to study entry.
• Prior Treatment:
• Excluded:
• • Major surgery within 30 days of study entry.